JCR2017 Scientific Meeting

 English Session

Last Update March 22, 2017

EULAR Session

Date : Friday, April 21 (9:00 - 11:00)

Venue:Room 2 "PALACE Room"

EUS

Responding to the Rheuma Map - towards sdutions in rheumatology

Chair
Tsuneyo Mimori Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University
Tomoyuki Saito Department of Orthopaedre Surgery, Yokohama City University Graduate School of Medicine
Speaker
EUS-1 Posttranslationally modified proteins -the key to auto- immunity in RA?
Gerd Burmester University Medicine Berlin, Germany
EUS-2 Pathway identification in inflammatory arthritis
Iain McInnes ARUK Professor of Rheumatology, Muirhead Professor of Medicine, University of Glasgow, UK
EUS-3 Strategies to Prevent and Treat Early Rheumatoid Arthritis
Johannes Bijlsma Dept of Rheumatology & Clinical Immunology, UMC Utrecht, The Netherlands

Symposium 2

Date : Thursday, April 20 (9:00 - 11:00)

Venue: Room 2 "PALACE Room"

S2

State of the Art in Sarcopenia, Frailty and Locomotive Syndrome

Chair
Sakae Tanaka Department of Orthopaedic Surgery, Faculty of Medicine, the University of Tokyo
Hidenori Arai National Center for Geriatrics and Gerontology
Speaker
S2-1 Sarcopenia in Asia: consensus report of the Asian Working Group for SarcopeniaM
Liang-Kung Chen et al. Aging and Health Research Center, National Yang Ming University/Center for Geriatrics and Gerontology, Taipei Veterans General Hospital
S2-2 Frailty and sarcopenia: 2017 update
Hidenori Arai National Center for Geriatrics and Georontology
S2-3 Epidemiology of the locomotive syndrome: 2017 update
Noriko Yoshimura et al. Department of Joint Disease Research, 22nd Century Medical and Research Center, The University of Tokyo
S2-4 Sarcopenia in rheumatoid arthritis patients
Motomu Hashimoto Department of the Control for Rheumatic Diseases, Kyoto University
S2-5 Cachexia and Rheumatoid Arthritis
Jochen Springer Innovative Clinical Trials Unit, Department of cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany

Symposium 8

Date : Friday, April 21 (8:45 - 11:15)

Venue:Room 2 "SUNPALACE Main Hall"

S8

Pathogenic and clinical significance of autoantibodies

Chair
Masataka Kuwana Department of Allergy and Rheumatology, Nippon Medical School
Tatsuya Atsumi Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine
Speaker
S8-1 Pathogenic roles of ACPA in RA
Lars Klareskog Karolinska Institute, Sweden
S8-2 A biological functions of autoantibodies in patients with systemic sclerosis
Yasushi Kawaguchi (Institute of Rheumatology, Tokyo Women's Medical University,Japan)
S8-3 Clinical significance of autoantibodies in neuropsychiatric systemic lupus erythematosus
Takao Fujii (Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan)
S8-4 Association between Myositis-Specific Autoantibodies and Pathophysiology in Inflammatory Myopathies
Takahisa Gono (Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan)
S8-5 Anti-neutrophil cytoplasmic antibody (ANCA) and neutrophil extracellular traps (NETs)
Akihiro Ishizu (Faculty of Health Sciences, Hokkaido University)
S8-6 Thrombotic/hemorrhagic diseases caused by autoantibodies
Shinsuke Yasuda (Division of Rheumatology, Endocrinology & Nephrology, Hokkaido University Graduate School of Medicine)

Symposium 12

Date : Friday, April 21 (15:50 - 18:20)

Venue:Room 2 "PALACE Room"

S12

Perspective of rheumatology in 2027: What shall we do now?

Chair
Yoshiya Tanaka University of Occuupational and Environmental Health
Gerd Burmester University Medicine Berlin
Speaker
S12-1 Rheumatology – to a brighter future in the next decade?
Iain McInnes ARUK Professor of Rheumatology, Muirhead Professor of Medicine, University of Glasgow, UK
S12-2 New molecule
Arthur Kavanaugh University of California, San Diego, USA
S12-3 Novel strategies in the treatment of rheumatoid arthritis
Gerd Burmester University Medicine Berlin, Germany
S12-4 From Japanese experiences with advanced aging
Tsutomu Takeuchi Division of Rheumatology, Keio University School of Medicine, Japan

Symposium 19

Date : Suturday, April 22 (14:50 - 17:20)

Venue:Room 2 "PALACE Room"

S19

Emerging paradigm shift in systemic lupus erythematosus (SLE)

Chair
Hideto Kameda Division of Rheumatology, Department of Medicine, Toho University (Ohashi Medical Center)
Nan Shen Shanghai Institute Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China
Speaker
S19-1 New insights into the pathogenesis of systemic lupus erythematosus : Finding novel players and therapeutic targets
Nan Shen Shanghai Institute Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China
S19-2 Clinical practice and management of systemic lupus erythematosus in Japan
Tatsuya Atsumi Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Japan
S19-3 Update on the therapy of lupus nephritis
Chi-Chiu Mok Department of Medicine, Tuen Mun Hospital, Hong Kong
S19-4 Upcoming treatment of SLE
Yoshiya Tanaka The First Department of Internal Medicine, School of Medicine University of Occupational & Environmental Health, Japan

Meet the Expert 5 (MTE 5)*

Date : Thursday, April 20 (14:40 - 15:40)

Venue:MTE Room 1 "Fukuoka Kokusai Center Training Room1"

Lecturer
MTE5 Management of patients with refractory RA
※Rheumatologist with certain years of experience

Josef S Smolen Medical University of Vienna, Austria
Assistant
Hideto Kameda Division of Rheumatology, Toho University

* Meet the Expert is a participative and educational lecture. Number of participants will be limited.

Luncheon Seminar1

Date : Thursday, April 20 12:20-13:20

Venue : FUKUOKA SUNPALACE Palace Room A+B

LS1

Reconsider about PsA from IL-17 side

Chair
Tatsuya Atsumi Hokkaido University Graduate School of Medicine
Speaker
LS1-1 Important thigs for the treatment of psoriatic arthritis; not to overlook various symptoms
Yuho Kadono Department of Orthopaedic Surgery, Saitama Medical University
LS1-2 Latest Therapies for the management of Psoriatic arthritis
- focus on IL-17A inhibitors (secukinumab)

Philip J. Mease University of Washington School of Medicine; Rheumatology Research, Swedish-Providence Medical System, USA
Sponsored

Novartis Pharma K.K.

Luncheon Seminar4

Date : Thursday, April 20 12:20-13:20

Venue : Fukuoka International Congress Center Small Conference Rooms 401+402+403

Chair
Yoshiya Tanaka The First Dept. of Internal Medicine, University of Occupational & Environmental Health
Speaker
LS4 Evidence based discussion in RA and SpA – what we need to figure out next?
Arthur Kavanaugh Univrsity of California, School of Medicine, USA
Sponsor

AbbVie GK/Eisai Co., Ltd.

Luncheon Seminar12

Date : Friday, April 21 11:45-12:45

Venue : Fukuoka International Congress Center Multi-purpose Hall 201+202

Chair
Kazuhiko Yamamoto Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo
Speaker
LS12 The changing landscape of biosimilars in rheumatology
Tore K. Kvien Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway/University of Oslo, Norway
Sponsor

Nippon Kayaku Co.,Ltd.

Evening Seminar3

Date : Thursday, April 20 17:00-18:30

Venue : Fukuoka International Congress Center Multi-purpose Hall 203+204

ES3

Next RA treatment in new era

Chair
Naoki Ishiguro Nagoya University Graduate School of Medicine
Speaker
ES3-1 Benefit of multi-target therapy
Kunihiro Yamaoka Keio University School of Medicine
ES3-2 Beyond treat to target - patient satisfaction and QOL
Peter C. Taylor University of Oxford, UK

Evening Seminar7

Date : Thursday, April 20 17:00-18:30

Venue : Fukuoka International Congress Center Medium-sized Conference Rooms 413+414

ES7

Potential of Tumor Necrosis Factor (TNF) Inhibitors
-True Remission in Rheumatoid Arthritis Demonstrated by New Evidence-

Chair
Sakae Tanaka Graduate School of Medicine and Faculty of Medicine, The University of Tokyo
Takao Fujii WAKAYAMA MEDICAL UNIVERSITY
Speaker
ES7-1 How Imaging can be used for managing clinical remission: The real value of remission for patients
Paul Emery Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, UK
ES7-2 Impact of Work Productivity and Activity Impairment from the Viewpoints of Patient-reported Outcomes and Health Economics: Magnitude of the Japan's First Large-scale Evidence (Results from a special drug-use investigation)
Eiichi Tanaka Institute of Rheumatology, Tokyo Women's Medical University
ES7-3 Treatment Holiday: Benefit of Early Intervention
-Significance of the Accumulated Evidence-

Shintaro Hirata Hiroshima University
Sponsored

AbbVie GK/Eisai Co., Ltd.

Evening Seminar8

Date : Thursday, April 20 17:00-18:30

Venue : Fukuoka International Congress Center International Conference Room 501

ES8

The trend of rheumatoid arthritis treatment in the world and Japan

Chair
Kazuhiko Yamamoto Graduate School of Medicine and Faculty of Medicine, The University of Tokyo
Yoshinari Takasaki Juntendo Koshigaya Hospital
Speaker
ES8-1 2016 Updated EULAR RA Management Recommendations in a Global Perspective
Josef Smolen Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Austria
ES8-2 The perspective of Japanese RA treatment considering 2016 EULAR Updated Recommendation
Tsutomu Takeuchi Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
Sponsored
Chugai Pharmaceutical Co., Ltd.

Evening Seminar11

Date : Friday, April 21 18:30-20:00

Venue : Fukuoka International Congress Center Multi-purpose Hall 201+202

ES11

Novel treatment Strategies of Anti TNF agents in RA

Chair
Yoshinari Takasaki Juntendo Koshigaya Hospital
Speaker
ES11-1 Consideration of tapering first line anti-TNF therapy in early rheumatoid arthritis
Paul Emery Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, UK
ES11-2 The Future Beyond the Sustained Remission
Yoshiya Tanaka University of Occupational and Environmental Health
Sponsored

Mitsubishi Tanabe Pharma Corporation./Janssen Pharmaceutical K.K.